Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 2
Submit an article Journal homepage
278
Views
34
CrossRef citations to date
0
Altmetric
Drug Evaluation

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Raf Crabbé Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Grégoire Vuagniaux Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Jean-Maurice Dumont Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Valérie Nicolas-Métral Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Judith Marfurt Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
&
Laura Novaroli Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
Pages 211-220 | Published online: 15 Dec 2008

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Carol Stanciu, Anca Trifan, Cristina Muzica & Catalin Sfarti. (2019) Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opinion on Pharmacotherapy 20:4, pages 379-384.
Read now
Nihar Shah, Tracey Pierce & Kris V Kowdley. (2013) Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opinion on Investigational Drugs 22:9, pages 1107-1121.
Read now
Robert Flisiak, Jerzy Jaroszewicz, Iwona Flisiak & Tadeusz Łapiński. (2012) Update on alisporivir in treatment of viral hepatitis C. Expert Opinion on Investigational Drugs 21:3, pages 375-382.
Read now
Robert Flisiak & Anna Parfieniuk. (2010) Investigational drugs for hepatitis C. Expert Opinion on Investigational Drugs 19:1, pages 63-75.
Read now

Articles from other publishers (30)

Yang Yang & Youhua Xie. 2022. Virus Entry Inhibitors. Virus Entry Inhibitors 199 205 .
Thomas Tu & Stephan Urban. (2018) Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Current Opinion in Virology 30, pages 68-79.
Crossref
Guanghai Jin, Jisu Lee & Kyeong Lee. (2017) Chemical genetics-based development of small molecules targeting hepatitis C virus. Archives of Pharmacal Research 40:9, pages 1021-1036.
Crossref
Matthew R Naylor, Andrew T Bockus, Maria-Jesus Blanco & R Scott Lokey. (2017) Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets. Current Opinion in Chemical Biology 38, pages 141-147.
Crossref
Lize Cuypers, Joke Snoeck, Lien Kerremans, Pieter Libin, Raf Crabbé, Sonia Van Dooren, Grégoire Vuagniaux & Anne-Mieke Vandamme. (2016) HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Infection, Genetics and Evolution 44, pages 169-181.
Crossref
Avantika Barve, Steven J. Kovacs, June Ke, Rafael Crabbe, Peter Grosgurin, Annick Menetrey, Valerie Nicolas-Métral, Kristina Dabovic, Kiran Dole, Jie Zhang, Jens Praestgaard, Gangadhar Sunkara & Daniel Stein. (2015) The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. Clinical Pharmacology in Drug Development 4:1, pages 25-32.
Crossref
T H T Nguyen, F Mentré, M Levi, J Yu & J Guedj. (2014) A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response. Clinical Pharmacology & Therapeutics 96:5, pages 599-608.
Crossref
Eliana G. Acosta, Anil Kumar & Ralf Bartenschlager. 2014. 1 109 .
Michael Peel & Andrew Scribner. 2013. Successful Strategies for the Discovery of Antiviral Drugs. Successful Strategies for the Discovery of Antiviral Drugs 384 418 .
Joseph S. Doyle, Esther Aspinall, Danny Liew, Alexander J. Thompson & Margaret E. Hellard. (2013) Current and emerging antiviral treatments for hepatitis C infection. British Journal of Clinical Pharmacology 75:4, pages 931-943.
Crossref
Philippe Gallay, Roger Ptak, Michael Bobardt, Jean-Maurice Dumont, Grégoire Vuagniaux & Brigitte Rosenwirth. (2013) Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms. Viruses 5:3, pages 981-997.
Crossref
Mario Arciello, Manuele Gori & Clara Balsano. (2013) Mitochondrial Dysfunctions and Altered Metals Homeostasis: New Weapons to Counteract HCV-Related Oxidative Stress. Oxidative Medicine and Cellular Longevity 2013, pages 1-10.
Crossref
Giovanni Quarato, Rosella Scrima, Francesca Agriesti, Darius Moradpour, Nazzareno Capitanio & Claudia Piccoli. (2013) Targeting mitochondria in the infection strategy of the hepatitis C virus. The International Journal of Biochemistry & Cell Biology 45:1, pages 156-166.
Crossref
Jennifer Y. Chen & Raymond T. Chung. (2012) Future Classes of Hepatitis C Virus Therapeutic Agents. Infectious Disease Clinics of North America 26:4, pages 949-966.
Crossref
Leiyun Weng, Xiao Tian, Yayi Gao, Koichi Watashi, Kunitada Shimotohno, Takaji Wakita, Michinori Kohara & Tetsuya Toyoda. (2012) Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro. Biochimica et Biophysica Acta (BBA) - General Subjects 1820:12, pages 1886-1892.
Crossref
Laurent Chatel-Chaix, Marie-Anne Germain, Matthias Götte & Daniel Lamarre. (2012) Direct-acting and host-targeting HCV inhibitors: current and future directions. Current Opinion in Virology 2:5, pages 588-598.
Crossref
Carrie L. Jennings & Kenneth E. Sherman. (2012) Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. Current HIV/AIDS Reports 9:3, pages 231-237.
Crossref
Giovanni Quarato, Annamaria D'Aprile, Bruno Gavillet, Grégoire Vuagniaux, Darius Moradpour, Nazzareno Capitanio & Claudia Piccoli. (2012) The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology 55:5, pages 1333-1343.
Crossref
Sandra B?hler & Ralf Bartenschlager. (2012) New targets for antiviral therapy of chronic hepatitis C. Liver International 32, pages 9-16.
Crossref
Francesco Azzaroli, Laura Turco, Andrea Lisotti, Paolo Cecinato, Claudio Calvanese, Federica Buonfiglioli, Monica Cevenini, Marco Montagnani & Giuseppe Mazzella. (2012) Alisporivir for the treatment of chronic HCV. Future Virology 7:1, pages 9-18.
Crossref
Steven J. Moss, Michael Bobardt, Pieter Leyssen, Nigel Coates, Udayan Chatterji, Xie Dejian, Teresa Foster, Jinlun Liu, Mohammad Nur-e-Alam, Dipen Suthar, Chen Yongsheng, Tony Warneck, Ming-Qiang Zhang, Johan Neyts, Philippe Gallay, Barrie Wilkinson & Matthew A. Gregory. (2012) Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection. Med. Chem. Commun. 3:8, pages 944-949.
Crossref
Edgar D. Charles & Ira M. Jacobson. 2012. Chronic Hepatitis C Virus. Chronic Hepatitis C Virus 131 148 .
Kay Seden & David Back. (2011) Directly acting antivirals for hepatitis C and antiretrovirals. Current Opinion in HIV and AIDS 6:6, pages 514-526.
Crossref
Matthew A. Gregory, Michael Bobardt, Susan Obeid, Udayan Chatterji, Nigel J. Coates, Teresa Foster, Philippe Gallay, Pieter Leyssen, Steven J. Moss, Johan Neyts, Mohammad Nur-e-Alam, Jan Paeshuyse, Mahmood Piraee, Dipen Suthar, Tony Warneck, Ming-Qiang Zhang & Barrie Wilkinson. (2011) Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family. Antimicrobial Agents and Chemotherapy 55:5, pages 1975-1981.
Crossref
Jarrod Bailey. (2010) An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model. Alternatives to Laboratory Animals 38:5, pages 387-418.
Crossref
K. Seden, D. Back & S. Khoo. (2010) New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy 65:6, pages 1079-1085.
Crossref
Francesco Negro. (2010) Adverse effects of drugs in the treatment of viral hepatitis. Best Practice & Research Clinical Gastroenterology 24:2, pages 183-192.
Crossref
R. F. Schinazi, L. Bassit & C. Gavegnano. (2010) HCV drug discovery aimed at viral eradication. Journal of Viral Hepatitis 17:2, pages 77-90.
Crossref
Sebastian Daum, Michael Schumann, Sebastian Mathea, Tobias Aumüller, Molly A. Balsley, Stephanie L. Constant, Boris Féaux de Lacroix, Fabian Kruska, Manfred Braun & Cordelia Schiene-Fischer. (2009) Isoform-Specific Inhibition of Cyclophilins. Biochemistry 48:26, pages 6268-6277.
Crossref
Nicholas A. Meanwell, John F. Kadow & Paul M. Scola. 2009. Annual Reports in Medicinal Chemistry Volume 44. Annual Reports in Medicinal Chemistry Volume 44 397 440 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.